Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...

A full-year 2024 trading update for Arecor Therapeutics shows revenue was up to £5.1million (2023: £4.6m) while cash and cash ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Another drugs that may be used off-label for GHI include Xeris' Gvoke brand of glucagon in pre-filled syringe and pen injector formulations, which was approved in 2019 as a hypoglycaemia rescue ...

Beta Bionics’ IPO marks one of the largest public offerings for an Orange County-based company in over three years, second ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Daniels says the shortage of brand name drugs like glucagon-like peptide-1 (GLP-1) medications to treat diabetes and obesity ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...